3 results
Approved WMOCompleted
The aim of this study is to investigate what proportion of HBeAg negative, inactive carriers of the hepatitis B virus with low (< 20,000 IU/mL) load will lose HBsAg when treated with nucleot(s)ide analogue/Peg-IFN combination therapy.
Approved WMORecruiting
This study is looking at how safe the combination of the experimental drugs dostarlimab, belrestotug and GSK6097608 is in patients with previously untreated, advanced or metastatic non-small cell lung cancer. And how well the combination works. We…
Approved WMOPending
To show differences in uptake of Primovist between FNHs and hepatocellular adenomas on CT.